Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
FibroGen Inc (NASDAQ: FGEN) closed the day trading at $0.35 down -21.80% from the previous closing price of $0.44. In other words, the price has decreased by -$21.80 from its previous closing price. On the day, 2.89 million shares were traded. FGEN stock price reached its highest trading level at $0.3946 during the session, while it also had its lowest trading level at $0.3117.
Ratios:
For a better understanding of FGEN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on August 08, 2023, Downgraded its rating to Underperform and sets its target price to $2 from $4 previously.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 12 ’24 when Adib Deyaa bought 22,123 shares for $1.17 per share. The transaction valued at 25,884 led to the insider holds 82,123 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FGEN now has a Market Capitalization of 35067960 and an Enterprise Value of 48784720. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.19. Its current Enterprise Value per Revenue stands at 0.271 whereas that against EBITDA is -0.425.
Stock Price History:
The Beta on a monthly basis for FGEN is 0.72, which has changed by -0.8525424 over the last 52 weeks, in comparison to a change of 0.07465422 over the same period for the S&P500. Over the past 52 weeks, FGEN has reached a high of $2.80, while it has fallen to a 52-week low of $0.18. The 50-Day Moving Average of the stock is -31.04%, while the 200-Day Moving Average is calculated to be -37.75%.
Shares Statistics:
Over the past 3-months, FGEN traded about 3.61M shares per day on average, while over the past 10 days, FGEN traded about 1495250 shares per day. A total of 100.77M shares are outstanding, with a floating share count of 94.13M. Insiders hold about 6.59% of the company’s shares, while institutions hold 36.16% stake in the company. Shares short for FGEN as of 1740700800 were 5299842 with a Short Ratio of 1.47, compared to 1738281600 on 2905867. Therefore, it implies a Short% of Shares Outstanding of 5299842 and a Short% of Float of 6.1899999999999995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The firm’s stock currently is rated by 1.0 analysts. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.22 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.53 and -$0.88 for the fiscal current year, implying an average EPS of -$0.7. EPS for the following year is -$0.71, with 2.0 analysts recommending between -$0.56 and -$0.86.
Revenue Estimates
1 analysts predict $2M in revenue for the current quarter. It ranges from a high estimate of $2M to a low estimate of $2M. As of the current estimate, FibroGen Inc’s year-ago sales were $55.9MFor the next quarter, 1 analysts are estimating revenue of $2M. There is a high estimate of $2M for the next quarter, whereas the lowest estimate is $2M.
A total of 2 analysts have provided revenue estimates for FGEN’s current fiscal year. The highest revenue estimate was $187.3M, while the lowest revenue estimate was $6M, resulting in an average revenue estimate of $96.65M. In the same quarter a year ago, actual revenue was $203.28MBased on 2 analysts’ estimates, the company’s revenue will be $105.5M in the next fiscal year. The high estimate is $205M and the low estimate is $6M.
